The 25 Biggest Insider Purchases in October

Page 9 of 25

17. Soligenix, Inc. Common Stock (NASDAQ:SNGX)

Who Bought Shares: Director Mark E. Pearson

How Many Shares Were Bought: 170,000 @ $1.16 per share

Date of the Transaction(s): October 17

In the span of less than two weeks in October, Soligenix, Inc. Common Stock (NASDAQ:SNGX) shares lost just under half of their value, which spurred two different insiders to buy some of them around the middle of the month. Soligenix is currently in phase 3 testing of SGX301, for the treatment of cancerous skin lesions in patients with cutaneous T-cell lymphoma (CTCL). Results from the phase 2 trial of the drug showed it to be safe and effective, with 58.3% of patients enjoying a significant response.

Follow Soligenix Inc. (NASDAQ:SNGX)

Page 9 of 25